Graft manipulation and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation from mismatched unrelated and mismatched/haploidentical related donors in pediatric leukemia patients
- PMID: 20216238
- DOI: 10.1097/MPH.0b013e3181cf813c
Graft manipulation and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation from mismatched unrelated and mismatched/haploidentical related donors in pediatric leukemia patients
Abstract
Transplant-related problems have been partially overcome by using reduced-intensity conditioning (RIC), graft engineering, and alternative donors. In all, 21 leukemia patients with no suitable donor received a hematopoietic stem cell transplantation from a mismatched/haploidentical related (n=16) or unrelated donor (n=5). Fludarabine-RIC and PBSC graft were used. Manipulation was done by CD34+ selection (n=9) or CD3/CD19 depletion (n=12). Results were compared with patients (n=26) conditioned with the same regimen and grafted with a CD34+-selected PBSC from identical related donors. Median time to neutrophil recovery was 12 days (range, 10-19 d). Platelet engraftment was faster with a CD3/CD19-depleted graft (median, 11 d; range, 9-21) than with a CD34+ graft (median, 14 d; range, 9-53; P=0.003). Full donor chimerism in bone marrow CD34+ cells was higher in CD3/CD19-depleted graft group compared with CD34+-selected group (P=0.02). CD3/CD19 depletion showed higher natural killer cell counts even after 1 year. Nonrelapse mortality (7% for matched CD34+-selected grafts and 11% for mismatched/haplo-CD3/CD19-depleted grafts), relapse probability (27% for related CD34+-selected patients and 33% for related CD3/CD19-depleted patients), and disease-free survival were similar for both the groups. In conclusion, using graft engineering procedures after RIC for hematopoietic stem cell transplantation offers a high probability of engraftment, fast immune recovery, and very low mortality even with mismatched donors.
Similar articles
-
Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.Blood Cells Mol Dis. 2008 Jan-Feb;40(1):13-9. doi: 10.1016/j.bcmd.2007.07.001. Epub 2007 Sep 14. Blood Cells Mol Dis. 2008. PMID: 17869547 Clinical Trial.
-
Haploidentical allogeneic hematopoietic cell transplantation in adults with reduced-intensity conditioning and CD3/CD19 depletion: fast engraftment and low toxicity.Exp Hematol. 2006 Dec;34(12):1746-52. doi: 10.1016/j.exphem.2006.08.009. Exp Hematol. 2006. PMID: 17157172 Clinical Trial.
-
Mismatched T cell-depleted hematopoietic stem cell transplantation for children with high-risk acute leukemia.Bone Marrow Transplant. 1998 Dec;22 Suppl 5:S29-32. Bone Marrow Transplant. 1998. PMID: 9989886 Clinical Trial.
-
Haploidentical transplantation for acute lymphoblastic leukemia in childhood.Blood Rev. 2004 Sep;18(3):181-92. doi: 10.1016/S0268-960X(03)00063-8. Blood Rev. 2004. PMID: 15183902 Review.
-
Fludarabine-based cytoreductive regimen and T-cell-depleted grafts from alternative donors for the treatment of high-risk patients with Fanconi anaemia.Br J Haematol. 2008 Mar;140(6):644-55. doi: 10.1111/j.1365-2141.2007.06975.x. Br J Haematol. 2008. PMID: 18302713 Review.
Cited by
-
T-cell depleted haploidentical hematopoietic cell transplantation for pediatric malignancy.Front Pediatr. 2022 Oct 14;10:987220. doi: 10.3389/fped.2022.987220. eCollection 2022. Front Pediatr. 2022. PMID: 36313879 Free PMC article. Review.
-
Prognostic factors and outcomes for pediatric patients receiving an haploidentical relative allogeneic transplant using CD3/CD19-depleted grafts.Bone Marrow Transplant. 2016 Sep;51(9):1211-6. doi: 10.1038/bmt.2016.101. Epub 2016 Apr 18. Bone Marrow Transplant. 2016. PMID: 27088380
-
Comparison of clinical outcomes between unrelated single umbilical cord blood and "ex-vivo" T-cell depleted haploidentical transplantation in children with hematological malignancies.World J Pediatr. 2021 Dec;17(6):609-618. doi: 10.1007/s12519-021-00461-w. Epub 2021 Sep 30. World J Pediatr. 2021. PMID: 34590210
-
Advancement of human leukocyte antigen-partially matched related hematopoietic stem cell transplantation.Front Med. 2013 Sep;7(3):306-15. doi: 10.1007/s11684-013-0279-x. Epub 2013 Jul 20. Front Med. 2013. PMID: 23888376 Review.
-
The outcomes of family haploidentical hematopoietic stem cell transplantation in hematologic malignancies are not associated with patient age.Biol Blood Marrow Transplant. 2011 Aug;17(8):1205-13. doi: 10.1016/j.bbmt.2010.12.703. Epub 2010 Dec 27. Biol Blood Marrow Transplant. 2011. PMID: 21193055 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical